The Bilateral 6-Hydroxydopamine-Lesioned Marmoset Model of Parkinson’s Disease

  • N. R. Hughes
  • I. J. Mitchell
  • J. M. Brotchie
Part of the Advances in Behavioral Biology book series (ABBI, volume 47)


Idiopathic Parkinson’s disease is a neurodegenerative disease of the dopaminergic neurons of the substantia nigra pars compacta. It is characterised by a triad of symptoms, bradykinesia, rigidity and resting tremor. Interspecies variation in the responses to treatment necesitates the use of primates in the development of novel approaches to the management of Parkinson’s disease. Several different primate models of Parkinson’s disease are commonly used, including the MPTP-treated macaque (Burns et al. 1983), the MPTP-treated marmoset (Brotchie et al. 1991; Close et al. 1990) and the unilateral 6-hydroxydopamine (6-OHDA)-lesioned marmoset (Annett et al. 1992). The MPTP-treated macaque is regarded as the ‘gold standard’ model as it accurately reproduces the pathology, symptoms and response to drug treatment seen in the idiopathic condition, including the development of levodopa-induced dyskinesias (Mitchell et al. 1989; Miller & Delong 1987; Bedard et al. 1986). However, poor availability and difficulty in breeding macaques limits their widespread usage. Problems with housing and handling are also encountered in using MPTP-treated macaques due to the large size of the animals.


Dopaminergic Neuron Parkinsonian Symptom Parkinsonian State Excitatory Amino Acid Transmission Marmoset Model 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Annett, L.E., Rogers, D.C., Hernandez, T.D., and Dunnett, S.B., 1992, Behavioural analysis of unilateral monoamine depletion in the marmoset, Brain 115: 825–856.PubMedCrossRefGoogle Scholar
  2. Bankiewicz, K.S., Plunkett, R.J., Jacobowitz, D.M., Porrino, L., Porzio, U., London, W.T., Kopin, I.J., and Oldfield, E.H., 1990, The effect of fetal mesencephalon implants on primate MPTP-induced parkinsonism, J. Neurosurg. 72: 231–244.PubMedCrossRefGoogle Scholar
  3. Bedard, P.J., Di Paolo, T., Falardeau, P., Boucher, R., 1986, Chronic treatment with L-DOPA, but not bromocriptene induces dyskinesias in MPTP-parkinsonian monkeys. Correlation with [3H]-spiperone binding, Brain Res. 379: 294–299.PubMedCrossRefGoogle Scholar
  4. Brotchie, J.M., Mitchell, I.J., Sambrook, M.A., Crossman, A.R., 1991, Alleviation of parkinsonism by antagonism of excitatory amino acid transmission in the medial segment of the globus pallidus in rat and primate, Mov. Disord. 6: 133–138.PubMedCrossRefGoogle Scholar
  5. Burns, R.S., Chiueh, C.C., Markey, S.P., Ebert, M.H., Jacobowitz, D.M., and Kopin, I.J., 1983, Aprimate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of substantia nigra by N-methy1-4-phenyl-1,2,3,6,-tetrahydropyridine, Proc. Natl. Acad. Sci., U.S.A. 80: 4546–4550.PubMedCrossRefGoogle Scholar
  6. Close, S.P., Elliot, P.J., Hayes, A.G., Marriott, A.S., 1990, Effects of classical and novel agents in a MPTP-in-duced reversible model of Parkinson’s disease. Psychopharmacol. 102: 295–300.CrossRefGoogle Scholar
  7. Miller, W.C., Delong, M.R., 1987, Altered tonic activity of neurons in the globus pallidus and subthalamic nucleus in the primate MPTP model of parkinsonism, in: The Basal Ganglia II, (A.B. Carpenter, A. Jayaraman, eds.), Plenum Press, New York, pp. 415–427.CrossRefGoogle Scholar
  8. Mitchell, I.J., Clarke, C.E., Boyce, S., Robertson, R.G., Peggs, D., Sambrook, M.A., Crossman, A.R., 1989, Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglu-cose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Neurosci. 32: 213–226.CrossRefGoogle Scholar
  9. Mitchell, I.J., Hughes, N.R., Carroll, C.B., and Brotchie, J.M., 1995, Reversal of parkinsonian symptoms by intrastriatal and systemic manipulations of excitatory amino acid and dopamine transmission in the bilateral 6-OHDA lesioned marmoset, Behav. Pharmacol. 6: 492–507.PubMedGoogle Scholar
  10. Ungerstedt, U., 1971, Adipsia and aphagia after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system, Acta. Physiol. Scand. Suppl. 367: 95–122.PubMedGoogle Scholar
  11. Waters, C.M., Hunt, S.P., Jenner, P., and Marsden, C.D., 1987, An immunohistochemical study of the acute and long-term effects of 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine in the marmoset, Neurosci. 23: 1025–1039.CrossRefGoogle Scholar
  12. Yang, S.C., Markey, S.P., Bankiewicz, K.S., London, W.T., Lunn, G., 1988, Recommended safe practises for the using of the neurotoxin MPTP in animal experiments, Lab. Anim. Sci. 38: 563–567.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • N. R. Hughes
    • 1
  • I. J. Mitchell
    • 2
  • J. M. Brotchie
    • 1
  1. 1.Division of Neuroscience, School of Biological SciencesUniversity of ManchesterManchesterUK
  2. 2.School of PsychologyUniversity of BirminghamBirminghamUK

Personalised recommendations